Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31026729 | 0.78 | CYP11B1 (0.46) | CYP11B2CYP11B1 | |
| SCHEMBL13079401 | 0.77 | CYP2A6 (0.52) | CYP2A6ATMCYP11B2CYP11B1ALPL | |
| SCHEMBL30296491 | 0.75 | CYP11B2 (0.43) | CYP11B2CYP11B1 | |
| SCHEMBL26469046 | 0.75 | CYP11B2 (0.43) | CYP11B2CYP11B1 | |
| SCHEMBL30296246 | 0.74 | CYP11B2 (0.41) | CYP11B2CYP11B1 | |
| SCHEMBL3715051 | 0.74 | ATM (0.69) | CYP2A6ATMCYP11B2CYP11B1S1PR1 | |
| SCHEMBL31049800 | 0.73 | CYP11B2 (0.55) | CYP2A6ATMCYP11B2CYP11B1S1PR1 | |
| SCHEMBL30296309 | 0.70 | CYP11B2 (0.42) | CYP11B2CYP11B1 | |
| SCHEMBL4432846 | 0.70 | CYP11B1 (0.63) | CYP2A6ATMCYP11B2CYP11B1S1PR1 | |
| SCHEMBL3715166 | 0.70 | EGFR (0.53) | CYP2A6ATMCYP11B2CYP11B1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | CYP2A6 396/4885ATM 4161/4885CYP11B2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.